Trastuzumab brengitecan

Antibody–drug conjugate

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-12.

Also in development:HER2-Positive Breast Cancer · Phase 3Ovarian Cancer · Phase 3Colorectal Cancer · Phase 3Biliary Tract Cancer · Phase 3Urothelial Carcinoma · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (10)
Biliary Tract Cancer
Colorectal Cancer
NCT07730489 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-08 – 2027-12 · Colorectal Cancer
What this study did
HER2-Positive Breast Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
NCT07545460 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-07 – 2028-12 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
Urothelial Carcinoma
NCT07869836 · SystImmune Inc.
2026-11 – 2029-12 · Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC), Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Bladder Ca, Bladder Cancer Recurrent, Bladder Cancer Stage IV, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder
What this study did
Other / comorbidity
NCT07152405 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-09-24 – 2027-06 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2/3 (1)
HER2-Positive Breast Cancer
NCT06891833 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-06-05 – 2028-12 · HER2-positive Breast Cancer
What this study did
Phase 2 (4)
HER2-Positive Breast Cancer
NCT06445400 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-06-19 – 2026-12 · HER2-positive Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07264816 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-02-03 – 2027-12 · Non-squamous Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07678957 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-08-31 – 2028-12 · Breast Cancer
What this study did
NCT06423885 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-12-24 – 2026-10 · HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 1/2 (3)
Non-Small Cell Lung Cancer
NCT06114511 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-04-24 – 2027-12 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06131450 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-02-29 – 2027-12 · Gynecological Malignancies
What this study did
NCT06031584 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-01-19 – 2026-12 · Her2-positive/Low-expression Urinary and Digestive Tract Tumors
What this study did
Phase 1 (3)
Biliary Tract Cancer
NCT06293898 · SystImmune Inc.
2024-02-09 – 2029-04-15 · Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
What this study did
Other / comorbidity
NCT05631964 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-01-05 – 2027-12 · Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors
What this study did
NCT05461768 · Sichuan Baili Pharmaceutical Co., Ltd.
2022-08-09 – 2027-12 · Breast Cancer, Locally Advanced or Metastatic Solid Tumor
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for HER2-Positive Breast Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trastuzumab Brengitecan: this drugPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistReliable signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (HB1801)Phase 3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
PyrotinibPhase 3Small moleculeEGFR/HER1, HER2, HER4not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2Partial signal
NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis.
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 3Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
BizrolertinibPhase 2/3Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2/3Antibody–drug conjugateHER2Partial signal
NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91).
EvorpaceptPhase 2Protein / enzyme therapeuticCD47not yet gradedNo reviewed efficacy summary in this indication
BBO-10203
Phase 1(overall)
Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trastuzumab brengitecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Phase 1Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid TumorsRecruiting
Est. primary completion 2026-12 · NCT05631964 · CT.gov ↗
What to watch
Phase 1Breast Cancer, Locally Advanced or Metastatic Solid TumorRecruiting
Est. primary completion 2026-12 · NCT05461768 · CT.gov ↗
What to watch
Phase 1/2Her2-positive/Low-expression Urinary and Digestive Tract TumorsRecruiting
Est. primary completion 2026-12 · NCT06031584 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06114511 · CT.gov ↗
What to watch
2027 (6)
January 2027 (1)
Phase 1/2Gynecological MalignanciesRecruiting
Est. primary completion 2027-01 · NCT06131450 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3HER2-low Breast CancerRecruiting
Est. primary completion 2027-05 · NCT06957886 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-06 · NCT07152405 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07264816 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07178795 · CT.gov ↗
What to watch
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07730489 · CT.gov ↗
What to watch
2028 (6)
December 2028 (6)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-12 · NCT07678957 · CT.gov ↗
What to watch
Phase 2/3HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-12 · NCT06891833 · CT.gov ↗
What to watch
Phase 3Ovarian CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07545460 · CT.gov ↗
What to watch
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-12 · NCT07606599 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07869836 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2028-12-15 · NCT06293898 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2029-12 · NCT07518173 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2031-10 · NCT06830889 · CT.gov ↗
What to watch

See the full readout calendar ↗